STK-009 administration enhanced the anti-tumor efficacy of anti-glypican 3 (GPC3) CAR-T cells (SYNCAR-002) in highly aggressive subcutaneous and intraperitoneal hepatocellular carcinoma models. Here, GPC3 is linked to neoplasm.